Tag
Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.
Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.
This review evaluates the prognostic value of Major Pathologic Response (MPR) in pancreatic ductal adenocarcinoma, analyzing its impact on survival and its potential to guide personalized adjuvant treatment strategies.
A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate
A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a use
